Vaxcyte, Inc. (PCVX)

4d ago, source: Yahoo Finance

-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout ...

Why Vaxcyte Inc (NASDAQ:PCVX) Stock Increased 6.39 percent in recent Trade?

5d ago, source: bovnews

Mizuho raised the price target for the Vaxcyte Inc (NASDAQ:PCVX) stock to “a Buy”. The rating was released on December 07, 2023, according to finviz. The research report from Needham has reiterated ...

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

13d ago, source:

SAN CARLOS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation ...

Buy Rating Affirmed for Vaxcyte Amid Promising Pipeline and Clear Milestones

12d ago, source:

Vaxcyte (PCVX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer ...

Vaxcyte Inc Ordinary Shares

12d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Vaxcyte COO sells over $184k in company stock

18d ago, source: Investing

In a recent move, Vaxcyte, Inc.'s (NASDAQ:PCVX) Chief Operating Officer, Jim Wassil, has sold a substantial amount of company stock. According to the latest SEC filings, Wassil parted with a total ...

Vaxcyte CEO sells $928,845 in stock, buys $26,850 worth

26d ago, source: Investing

SAN CARLOS, CA – Vaxcyte, Inc. (NASDAQ:PCVX) reported a significant transaction by its Chief Executive Officer, Grant Pickering. According to the latest filing, Pickering sold 15,000 shares of the ...

Vaxcyte CEO sells over $161k in company stock

18d ago, source: Investing

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering has sold a portion of his holdings in the company, according to a recent filing with the Securities and Exchange Commission. The transactions, which ...

STRO Sutro Biopharma, Inc.

2d ago, source: Seeking Alpha

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated ...

Vaxcyte Inc.

22d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

13d ago, source: Business Insider

-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout ...